Japan Producer Inflation Eases to 7.6% in August 
US Bans Canadian Alcohol, Motorcycles as Trade War Escalates 
Norway Core Inflation Rises to 3% in August 
Oil Prices Surge as Middle East Shipping Attacks Threaten Supply 
German Inflation Accelerates to 2.9% in August 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Asian Stocks Fall as Oil Tops $100, Yields Rise 
UK Economy Grows 0.4% in July, Beating Forecasts 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Apple Unveils $1,999 Foldable iPhone Duo 
Zara Owner Inditex Sales Rise 9% in August 
Oil Prices Hold Near Highs as U.S.-Iran Conflict Escalates 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028 
China Buys 1 Million Tons of U.S. Soybeans Ahead of Xi Visit 
UK Businesses Urge Government to Cut Electricity Levies 
Samsung, Qualcomm 2nm Chip Deal Delayed Over Pricing 
Add as a preferred source on Google
Tokyo Medical and Dental University and the National Center of Neurology and Psychiatry are planning to develop tailored drugs for patients with genetic disorders to find treatment for extremely rare diseases.
The two Japanese medical institutions will search for rare diseases that have the potential to be treated by nucleic acid drugs from a database of around 2,250 patients.
Nucleic acid drugs are an emerging class of therapeutics,
The development will be carried out based on technology that targets the expression of disease-causing proteins in the mutant gene.
Due to the price and challenges with financial viability, pharmaceutical companies are hesitant to develop medications for exceedingly rare disorders.
According to Takanori Yokota, a professor of neurology and neurological science at Tokyo Medical and Dental University, they hope to make effective patient-tailored nucleic acid drugs and find as many people who can be treated.
The Initiative on Rare and Undiagnosed Diseases, a study that examines the DNA of people whose diseases cannot be detected or for which there is no known cure, will be used to pick participants from among the patients registered in it.
The project catalogs approximately 1,700 linked gene sequences and covers a wide spectrum of illnesses, such as neurological, cardiac, and metabolic problems.
In Japan, only one or two family lines are affected by about 70% of the diseases, and many do not have any reliable treatments.
In addition to the causative gene, factors such as age, the severity of symptoms, and the speed at which the disease is progressing will be taken into account when choosing candidate patients.
